Mr. Speaker, the federal government recognizes the challenges faced by Canadians with rare disorders, including the fact that few and expensive treatment options exist and they are difficult to assess due to the inherent limited availability of data. The Government of Canada remains committed to assisting provinces and territories with the cost of their health care system, as underscored in the Speech from the Throne and in the 2010 budget. While provinces and territories have jurisdiction over the delivery of health care, these funds can help with the costs of their drug plans, including public drug programs covering people suffering from rare disorders.
Orphan drugs are often not recommended by the common drug review for formulary listing as they typically fail the test for cost-effectiveness due to their high costs and limited evidence of long-term effectiveness. Participating jurisdictions retain the ability to make listing decisions based on their respective needs and priorities. In fact, some provinces, Alberta and Ontario, have moved forward with their own programs specifically designed for drugs for rare diseases. The government is prepared to work with interested provinces and territories to explore new approaches to assessing treatment options for rare diseases for potential reimbursement by the respective drug programs.
The federal government regulates the authorization process of pharmaceuticals with regard to their safety and efficacy. Health Canada is exploring a new regulatory framework to address issues specific to drugs for rare diseases, such as appropriate pre-market and post-market requirements given small populations. Technical consultations with key stakeholders are under way and will continue over the coming months.